Fred Alger Management’s Acorda Therapeutics ACOR Stock Holding History

Fred Alger Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,664	Closed	-$2.29M	–	534
2019 Q3	$2.29M	Sell	6,664 -374	-5%	-$203K	0.01%	276
2019 Q2	$6.48M	Buy	7,038 +1,014	+17%	+$1.25M	0.02%	205
2019 Q1	$9.61M	Buy	6,024 +1,698	+39%	+$3.06M	0.04%	185
2018 Q4	$8.09M	Buy	4,326 +48	+1%	+$104K	0.04%	185
2018 Q3	$10.1M	Buy	4,278 +1,543	+56%	+$4.78M	0.04%	182
2018 Q2	$9.42M	Sell	2,735 -366	-12%	-$1.12M	0.04%	183
2018 Q1	$8.8M	Buy	+3,101	New	+$9.29M	0.04%	185
2013 Q4	–	Sell	-5,705	Closed	-$23.4M	–	602
2013 Q3	$23.4M	Buy	5,705 +63	+1%	+$271K	0.13%	182
2013 Q2	$22.3M	Buy	+5,642	New	+$23.2M	0.13%	183

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Fred Alger Management's ACOR Position: Q4 2019 in Review

Fred Alger Management sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 6,664 shares — an estimated $2.29M sold.

Fred Alger Management first reported a position in ACOR in Q2 2013 and held it in 9 quarters. The position peaked at $23.4M in Q3 2013. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

Fred Alger Management reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
Fred Alger Management sold 6,664 Acorda Therapeutics shares in Q4 2019, an estimated $2.29M.
Fred Alger Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 9 quarters.
Fred Alger Management's Acorda Therapeutics position peaked at $23.4M in Q3 2013.
121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Fred Alger Management's 13F filing for Q4 2019, filed 14 Feb 2020.